Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

INTRODUCTION: In the absence of head-to-head trials, this analysis aimed to provide a fair indirect comparison of the efficacy between blinatumomab and inotuzumab ozogamicin (InO), two treatments for adult patients with relapsed or refractory acute lymphoblastic leukemia (R/R ALL) who received no mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Jinlin, Ma, Qiufei, Gao, Wei, Cong, Ze, Xie, Jipan, Zimmerman, Zachary, Belton, Laura, Franklin, Janet, Palmer, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824351/
https://www.ncbi.nlm.nih.gov/pubmed/30758745
http://dx.doi.org/10.1007/s12325-019-0873-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824351/
https://www.ncbi.nlm.nih.gov/pubmed/30758745
http://dx.doi.org/10.1007/s12325-019-0873-7

Ejemplares similares